
Media
Media
Our latest press releases
Hansa Biopharma publishes Annual Report 2022
Regulatory press release
30/03/2023
Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation
Regulatory press release
29/03/2023
Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
03/03/2023
Hansa Biopharma Year-end report January-December 2022
Regulatory press release
02/02/2023
Media
News and insights
Acknowledging Disparities Between Sexes in Kidney Transplantation this World Kidney Day
09/03/2023
Pride and commitment: how we shape Hansa into a truly great place to work
30/09/2022
Understanding the individual unmet needs of highly sensitized patients awaiting kidney transplant
10/03/2022
Time is a key factor: a spotlight on people affected by Guillain-Barré Syndrome
28/02/2022
Meetings of interest
Impactful interaction with the scientific and medical community
At Hansa, we are focused on the bigger picture and want help rare disease patients live long and healthy lives. We do this also by constant engagement with the scientific and healthcare communities. We use this opportunity to not only raise awareness about the unmet needs of the patients, but also to help advance the understanding in these complex fields. Meetings of interest